2018
DOI: 10.1128/cmr.00048-18
|View full text |Cite
|
Sign up to set email alerts
|

Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives

Abstract: SUMMARYResearch in visceral leishmaniasis in the last decade has been focused on how better to use the existing medicines as monotherapy or in combination. Systematic research by geographical regions has shown that a universal treatment is far from today's reality. Substantial progress has been made in the elimination of kala-azar in South Asia, with a clear strategy on first- and second-line therapy options of single-dose liposomal amphotericin B and a combination of paromomycin and miltefosine, respectively,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
206
0
6

Year Published

2019
2019
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 177 publications
(212 citation statements)
references
References 98 publications
0
206
0
6
Order By: Relevance
“…The current drug regimens, while allowing progress towards eliminating kala-azar, will probably be inadequate for the post-elimination phase. 25 Based on WHO recommendations, the kala-azar elimination programme replaced miltefosine with a single dose infusion of liposomal amphotericin B (AmBisome) as first line treatment in 2013. AmBisome has shown greater efficacy and improved compliance, but it requires a strict cold chain.…”
Section: Priorities To Sustain Eliminationmentioning
confidence: 99%
“…The current drug regimens, while allowing progress towards eliminating kala-azar, will probably be inadequate for the post-elimination phase. 25 Based on WHO recommendations, the kala-azar elimination programme replaced miltefosine with a single dose infusion of liposomal amphotericin B (AmBisome) as first line treatment in 2013. AmBisome has shown greater efficacy and improved compliance, but it requires a strict cold chain.…”
Section: Priorities To Sustain Eliminationmentioning
confidence: 99%
“…Overall, the development of VL treatments globally has had successes but also many pitfalls. 105,106…”
Section: A Global Review Of Visceral Leishmaniasismentioning
confidence: 99%
“…127 In 2003 the Drugs for Neglected Disease Initiative (DNDi) organized a network of stakeholders bringing together Ethiopia, Kenya, Sudan and Uganda together to create the Leishmaniasis East Africa Platform (LEAP). 128 The main work of the group has been, in furtherance of DNDi's mission which is, as the name suggests, to develop better treatment for NTDs, 106,129 A powerful approach to address VL, especially in the sub-Saharan Africa region with highest burden of infectious diseases, is to use integrated interventions. One study has assessed the integration landscape in 25 countries from all NTDs endemic region.…”
Section: A Global Review Of Visceral Leishmaniasismentioning
confidence: 99%
See 2 more Smart Citations